Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
55
Drug Approvals
EXELON 9.5MG-24H TRANSDERMAL PATCHES
- Approval Date
- Jul 18, 2025
- Company
- lts lohmann therapie-systeme
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (1017 trials with phase data)• Click on a phase to view related trials
A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 435
- Registration Number
- NCT06705504
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
- Conditions
- Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 42494
- Registration Number
- NCT06671314
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 376
- Registration Number
- NCT06662825
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1665
- Registration Number
- NCT06662812
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3632
- Registration Number
- NCT06644638
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 143
- Next
News
Voyager Therapeutics Advances Multi-Modal Neurotherapeutics Pipeline with Novel NeuroShuttle Platform and TDP-43 Collaboration
Voyager Therapeutics introduced its Voyager NeuroShuttle platform, a nonviral delivery system that demonstrated sustained brain expression over three weeks in murine studies, significantly longer than transferrin receptor shuttles.
CCP Approves Getz Group's Acquisition of Novartis Pakistan in Major Pharmaceutical Transaction
The Competition Commission of Pakistan has approved International Investment II Limited's acquisition of Novartis Pharma (Pakistan) Limited following a Phase-I competition review under the Competition Act 2010.
Genmab Reports Strong Q3 2025 Results with Key Pipeline Advances and $8 Billion Merus Acquisition
Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.
Moberg Pharma Partners with Karo Healthcare to Launch Breakthrough Topical Nail Fungus Treatment Across Europe
Moberg Pharma has entered an exclusive licensing agreement with Karo Healthcare to commercialize MOB-015/Terclara across 19 European markets representing 500 million people.
Meharry Medical College and Novartis Launch Five-Year HEART Initiative to Combat Cardiovascular Disease Disparities
The School of Global Health at Meharry Medical College and Novartis have launched the Health Assessments and Rapid Transformation (HEART) initiative, a five-year program targeting cardiovascular disease disparities in three US cities.
Galapagos Appoints New Board Directors to Accelerate Business Development Strategy
Galapagos has appointed Dr. Neil Johnston and Devang Bhuva to its Board of Directors effective November 1, 2025, bringing extensive business development and financial leadership expertise.
Breckenridge Launches Generic Everolimus 1mg Tablets, Completing Full Strength Portfolio for Transplant Patients
Breckenridge Pharmaceutical launched Everolimus Tablets 1mg, a generic version of Novartis' Zortress, completing their full strength portfolio of this immunosuppressant medication.
Novartis Reports 6% Operating Income Growth Driven by New Drug Portfolio Performance
Novartis reported third-quarter operating income of $5.46 billion, representing a 6% increase driven by growth in new drug sales that offset stagnant revenue from established treatments.
Abivax Phase III Success Triggers 850% Stock Surge, Reignites European Biotech Rally
Abivax shares soared over 850% following positive Phase III data in ulcerative colitis, creating an "Abivax effect" that has reshaped market dynamics and reignited investor confidence in European biotech.
Novartis' Cosentyx Achieves Primary and Secondary Endpoints in Phase III Polymyalgia Rheumatica Trial
Novartis announced that Cosentyx (secukinumab) successfully met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial for polymyalgia rheumatica treatment.